Clinical Trial Update: Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lirilumab in combination with rituximab for relapsed/refractory or high-risk untreated chronic lymphocytic leukemia; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)
• lirilumab (lirilumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-05-26